In a view to focus on research in inhalation and on complex formulations, Pharma major Lupin is in the process of setting up two dedicated Centres of Excellence for research in inhalation and complex injectables in Florida and Maryland in the US.
The company had also increased research and development spending to Rs 958.28 crore in FY 14 as compared to Rs 770.85 crore in the FY 13.
The company continues to invest heavily in its Research and Development (R&D) programmes and in FY 2014, the company invested 8.6% of its net sales in R&D and related spends, amounting to Rs 958.30 crore. It had invested 8.1% of its net sales in R&D and related spends amounting to Rs 770.85 crore in FY 13.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.70 |
| Dr. Reddys Labs. | 1356.85 |
| Cipla | 1465.15 |
| Zydus Lifesciences | 1112.20 |
| Lupin | 2420.15 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: